NCT02935725View on ClinicalTrials.gov

A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males

PHASE1CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

November 30, 2017

Study Completion Date

November 30, 2017

Conditions
Schizophrenia
Interventions
DRUG

Low dose AUT00206 800mg

DRUG

High dose AUT00206 2000 mg

DRUG

Placebo

DRUG

Ketamine

OTHER

Saline

Trial Locations (1)

Unknown

University Of Manchester, London

Sponsors
All Listed Sponsors
collaborator

University of Manchester

OTHER

lead

Autifony Therapeutics Limited

INDUSTRY

NCT02935725 - A Study to Assess the pharmacoMRI Effects of AUT00206 in Healthy Males | Biotech Hunter | Biotech Hunter